These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 19144987)
1. Quantitation of anti-factor VIII antibodies in human plasma. Krudysz-Amblo J; Parhami-Seren B; Butenas S; Brummel-Ziedins KE; Gomperts ED; Rivard GE; Mann KG Blood; 2009 Mar; 113(11):2587-94. PubMed ID: 19144987 [TBL] [Abstract][Full Text] [Related]
2. Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects. Batlle J; Gómez E; Rendal E; Torea J; Lourés E; Couselo M; Vila P; Sedano C; Tusell X; Magallón M; Quintana M; González-Boullosa R; López-Fernández MF Ann Hematol; 1996 May; 72(5):321-6. PubMed ID: 8645745 [TBL] [Abstract][Full Text] [Related]
3. Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay. Boylan B; Rice AS; Dunn AL; Tarantino MD; Brettler DB; Barrett JC; Miller CH; ; J Thromb Haemost; 2015 Jan; 13(1):47-53. PubMed ID: 25354263 [TBL] [Abstract][Full Text] [Related]
4. Factor VIII hydrolysis mediated by anti-factor VIII autoantibodies in acquired hemophilia. Wootla B; Dasgupta S; Dimitrov JD; Bayry J; Lévesque H; Borg JY; Borel-Derlon A; Rao DN; Friboulet A; Kaveri SV; Lacroix-Desmazes S J Immunol; 2008 Jun; 180(11):7714-20. PubMed ID: 18490775 [TBL] [Abstract][Full Text] [Related]
5. Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors. Miller CH; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; J Thromb Haemost; 2017 Oct; 15(10):1971-1976. PubMed ID: 28795528 [TBL] [Abstract][Full Text] [Related]
6. The humoral response to human factor VIII in hemophilia A mice. Healey JF; Parker ET; Barrow RT; Langley TJ; Church WR; Lollar P J Thromb Haemost; 2007 Mar; 5(3):512-9. PubMed ID: 17181826 [TBL] [Abstract][Full Text] [Related]
7. Induction of human factor VIII inhibitors in rats by immunization with human recombinant factor VIII: a small animal model for humans with high responder inhibitor phenotype. Jarvis MA; Levin LG; Harrison JA; DePianto DJ; Suzuki CM; Ziaja CL; Brown JE; Jolly KW; Reisner HM; Abildgaard CF; Powell JS Thromb Haemost; 1996 Feb; 75(2):318-25. PubMed ID: 8815584 [TBL] [Abstract][Full Text] [Related]
9. A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. Irigoyen MB; Primiani L; Felippo M; Candela M; Bianco RP; De Bracco MM; Galassi N Haemophilia; 2011 Mar; 17(2):267-74. PubMed ID: 21070488 [TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypes to factor VIII antibodies and their possible role in the pathogenesis and treatment of factor VIII inhibitors. Moffat EH; Furlong RA; Dannatt AH; Bloom AL; Peake IR Br J Haematol; 1989 Jan; 71(1):85-90. PubMed ID: 2492821 [TBL] [Abstract][Full Text] [Related]
11. Antibodies to the FVIII light chain that neutralize FVIII procoagulant activity are present in plasma of nonresponder patients with severe hemophilia A and in normal polyclonal human IgG. Moreau A; Lacroix-Desmazes S; Stieltjes N; Saenko E; Kaveri SV; D'Oiron R; Sultan Y; Scandella D; Kazatchkine MD Blood; 2000 Jun; 95(11):3435-41. PubMed ID: 10828026 [TBL] [Abstract][Full Text] [Related]
12. Alloantibodies to factor VIII in haemophilia. Zakarija A; Harris S; Rademaker AW; Brewer J; Krudysz-Amblo J; Butenas S; Mann KG; Green D Haemophilia; 2011 Jul; 17(4):636-40. PubMed ID: 21299745 [TBL] [Abstract][Full Text] [Related]
13. In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic. Scandella DH; Nakai H; Felch M; Mondorf W; Scharrer I; Hoyer LW; Saenko EL Thromb Res; 2001 Mar; 101(5):377-85. PubMed ID: 11297754 [TBL] [Abstract][Full Text] [Related]
14. Effects of pre-analytical heat treatment in factor VIII (FVIII) inhibitor assays on FVIII antibody levels. Boylan B; Miller CH Haemophilia; 2018 May; 24(3):487-491. PubMed ID: 29461004 [TBL] [Abstract][Full Text] [Related]
15. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice. Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232 [TBL] [Abstract][Full Text] [Related]
16. Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. Miller CH; Rice AS; Boylan B; Shapiro AD; Lentz SR; Wicklund BM; Kelly FM; Soucie JM; J Thromb Haemost; 2013 Jul; 11(7):1300-9. PubMed ID: 23601690 [TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A. Batty P; Moore GW; Platton S; Maloney JC; Palmer B; Bowles L; Pasi KJ; Rangarajan S; Hart DP Thromb Haemost; 2015 Oct; 114(4):804-11. PubMed ID: 26063073 [TBL] [Abstract][Full Text] [Related]
18. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671 [TBL] [Abstract][Full Text] [Related]
19. Screening of F.VIII:C antibodies by an enzyme-linked immunosorbent assay. Mondorf W; Ehrenforth S; Vigh Z; Last J; Tippmann G; Kreuz W; Scharrer I Vox Sang; 1994; 66(1):8-13. PubMed ID: 8146988 [TBL] [Abstract][Full Text] [Related]
20. Catalytic antibodies to factor VIII in haemophilia A. Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S31-4. PubMed ID: 14567533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]